CDA Formulations as the Best Drugs to Turn Around Cancer Mortality from Escalation to Deceleration
Author(s):
Ming C Liau*, Christine L Craig and Linda L Baker
The objective of this article is to rectify cancer therapies to turn around cancer mortality from escalation to deceleration. Cancer therapy had a bad start to rely on toxic chemicals to kill cancer cells (CCs). That was an unintentional mistake made by cancer establishments at a time we did not have complete knowledge of cancer. The incidence of cancer keeps on increasing as the world becomes more industrialized. The escalation of cancer incidence and the mishandling of cancer therapies stir up cancer as a giant killer to claim 10 million casualty worldwide a year. Now we have better knowledge of cancer. We know better ways to put out cancer. Unfortunately, the health profession is an authoritarian profession. When the mistake is made at the very top, there is no mechanism to rectify the mistake. Cancer patients continue to suffer.
Cancer stem cells (CSCs) became known in 1997. The discovery of CSCs unraveled a very important issue of cancer. It became evident that, although CSCs constituted only a very small side population, these cells were responsible for the initiation of tumor growth, and the treatment failure. Thus, elimination of CSCs is essential to the success of cancer therapy. Our studies of abnormal methylation enzymes (MEs), chemo-surveillance, wound healing and cell differentiation agent (CDA) formulations are closely related to CSCs. Therefore, we are in a unique position to offer CDA formulations as the best solution of CSCs and CCs to put out cancer to turn around cancer mortality from escalation to deceleration. The therapeutic endpoint of CDA formulations is terminal differentiation of CSCs and CCs that cannot make tumor to disappear. The tumor residue is harmless. If it is a concern, it can be safely removed by surgery.
